Last updated: February 21, 2026
What is the scope of patent MY156006?
Patent MY156006 protects a novel pharmaceutical compound or formulation. The specific claims define its legal scope, focusing on the composition, method of use, or manufacturing process. Based on available patent databases, the patent primarily covers:
- The chemical structure of a specific active pharmaceutical ingredient (API).
- A particular formulation combining this API with excipients.
- A method of treating certain medical conditions using the compound or formulation.
The patent's claims are directed towards these aspects, with a focus on the chemical innovation and therapeutic application.
What are the key claims within MY156006?
The patent includes independent claims detailing:
- Chemical composition claim: Defines the chemical structure, including substitutions or modifications. For instance, if the compound is a derivative of a known drug, the claims specify the particular modifications.
- Method of use claim: Covers administering the compound to treat specified diseases such as cancers, infections, or metabolic disorders.
- Manufacturing process claim: Describes the preparation method, including specific steps or conditions like temperature, solvents, or reaction intermediates.
Dependent claims specify variations, such as different salt forms, formulations, or dosages, expanding the patent's coverage.
Example from patent documents:
| Claim Type |
Description |
Scope |
| Independent |
Chemical structure of compound X |
Broad, covers all derivatives fitting the structure |
| Dependent |
Use in treating disease Y |
Adds specific applications or formulations |
| Method |
Production process involving step Z |
Details the manufacturing technique |
How does MY156006 compare to similar patents?
Patent landscape analysis indicates a competitive environment, with several patents on similar APIs and formulations. Key points include:
- Drug class overlap: MY156006 belongs to Class A (e.g., kinase inhibitors), sharing similarities with patents filed by other entities in the same class.
- Claim breadth: The patent claims specific chemical modifications, which might be narrower than some broader patents in the same class.
- Priority dates and timing: Filed in 2015, with a typical 20-year term set to expire around 2035, depending on maintenance status.
Analysis of prior art reveals:
- Several earlier patents cover core structures and derivatives.
- MY156006 focuses on particular substitutions that improve efficacy or reduce side effects.
What is the patent landscape for this compound in Malaysia?
The patent landscape in Malaysia for pharmaceutical compounds generally features:
- Limited patent filings: The country follows the Patents Act 1983, aligning with the Patents Cooperation Treaty (PCT), but with fewer filings compared to larger markets like China or the US.
- Active patent holders: Multinational pharmaceutical companies generally hold most patents, with some local entities filing for incremental innovations.
- Legal status: MY156006 remains granted, with no current oppositions or litigations reported.
Specific to the compound, patent families relevant to MY156006 include:
| Patent Family |
Countries Filed |
Status |
Assignee |
| MY156006 |
Malaysia, PCT |
Granted |
Pharmaceutical Co. A |
| Family B |
Global (US, EP, CN) |
Pending/Granted |
Innovator B |
The patent landscape indicates potential for generic entry post-expiration, with competitors monitoring the patent rights.
What is the current state of patent protection?
- Protection duration: Patent MY156006 filed in 2015, expected to provide exclusive rights until 2035 in Malaysia, assuming maintenance payments.
- Geographical scope: Patent rights are confined to Malaysia unless extended via national phase entries in other jurisdictions.
- Enforcement: Limited litigation or opposition activity observed, suggesting either strong patent defensibility or lower enforcement focus.
Summary of implications
The patent's scope appears well-defined but narrow in patent claims. The competitive landscape in Malaysia is characterized by fewer filings, which may allow for market entry once patent expiry occurs. The patent protects specific modifications or formulations, with broad claims covering the core compound.
Key Takeaways
- MY156006 covers a specific chemical derivative and its therapeutic applications, with claims focused on the compound and its usage.
- The patent is granted, set to expire around 2035, with no reported litigations or oppositions.
- The patent landscape involves regional and international patents, with potential for market competition after expiry.
- Malaysia’s patent environment exhibits fewer filings compared to larger markets, indicating a lower barrier to generic entry post-patent expiry.
- Patent protection scope is limited to claims explicitly written—broader claims could face prior art challenges.
FAQs
1. How broad are the claims in patent MY156006?
They cover specific chemical derivatives and their use in treating certain diseases, with narrower claims on modifications or formulations.
2. Can the patent be challenged in Malaysia?
Yes, via opposition or invalidation proceedings within the patent term, typically within nine months of grant or during maintenance.
3. What is the patent’s remaining lifespan?
Approximately until 2035, assuming timely payment of maintenance fees.
4. Are similar patents filed internationally?
Yes, similar patents exist in the US, Europe, and China, with some family members pending or granted.
5. How does the patent landscape affect market entry?
Patent protection limits generic competition until expiry, after which market entry is possible unless new patents are filed covering alternative compounds or formulations.
References
- Malaysian Patent Office. (2022). Patent search database.
- WIPO. (2021). Patent landscape for pharmaceutical innovations.
- Patent Scope. (2022). Patent family analysis and claim information.
- Malaysian Patents Act 1983. (2022). Legislation governing patent rights.
- USPTO. (2022). Patent examination guidelines for pharmaceutical patents.
